In a randomized, double-blind, placebo-controlled study involving 62 patients with heart failure (class II-IV), results indicate that supplementation with Carni Q-gel (ubiquinol + carnitine; Tishcon Corporation) may exert beneficial effects.
The patients were randomized to supplementation with Carni Q-gel (2250 mg/d L-carnitine + 270 mg/d hydrosoluble ubiquinol) (n=31) or placebo (n=31), for a period of 12 weeks.
At intervention-end, only patients in the Carni Q-gel-group showed a marked reduction in serum concentrations of interleukin-6 - a pro-inflammatory cytokine - compared to baseline.
Additionally, patients in the Carni Q-gel-group showed a greater decrease in TNF-alpha compared to patients in the placebo-group.
At intervention end, significant improvements in dyspnea, palpitation and fatigue (assessed using the quality of life visual analogous scale) were observed in the Carni Q-gel-group, compared with the placebo-group.
Furthermore, at intervention end, patients in the Carni Q-gel group showed significant improvements in the six-minute walk test and symptom scale, compared to patients in the placebo-group.
Thus, the authors of this study conclude, "These findings indicate that treatment with ubiquinol + L-carnitine can cause a significant reduction in the pro-inflammatory cytokines that are neurohumoural precursors related to sympathetic and parasympathetic activity, which is impaired in patients with heart failure.
There was a significant improvement in quality of life as well as decrease in NYHA-defined heart failure."
These results suggest that patients with heart failure may benefit from supplementation with a combination of carnitine and ubiquinol, as found in the Carni Q-gel supplement used in this study.